The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer
Abstract
Macrophages are polarized into two functionally distinct forms, M1 and M2, in response to different microenvironment. Tumor-associated macrophages (TAMs) generally have M2 phenotype and promote tumor progression. Few studies to date have described the infiltration of M2-polarized macrophages in ovarian cancer. We used two macrophages markers, CD68 and CD163, to analyze the expression of TAMs and to clarify the relationship between the M2 form and survival in advanced ovarian cancer. Clinical data of 110 patients with stages III-IV epithelial ovarian cancer at Sun Yat-sen University Cancer Center between 1999 and 2007 were retrospectively reviewed. Immunohistochemical staining of CD68 and CD163 was performed. Correlations between macrophage density and patient survival were analyzed. Our data showed that no significant difference was observed in survival between patients in the high- and the low-CD68 expression groups. In contrast, the progression-free survival (PFS) rates ( p = 0.003) and overall survival (OS) rates ( p = 0.004) were significantly higher in the low-CD163 expression group than in the high-CD163 expression group, respectively. Similarly, we also observed significantly improved 3-year PFS (49.8% vs. 11.0%, p < 0.001) and OS (77.4% vs. 45.0%, p < 0.001) rates in patients in the low-CD163/CD68 ratio group when compared with the high-CD163/CD68 ratio group. Multivariate analysis identified the density of CD163-positive cells as well as the ratio of CD163/CD68 as negative predictors for PFS and OS, respectively. Our results show that the infiltration of CD163-positive M2 macrophages as well as activation of macrophages towards the M2 phenotype may contribute to poor survival in advanced ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534 · cited 3×
“Macrophages are a heterogeneous population of cells derived from monocytes and polarized into two functionally distinct forms, M1 and M2, in response to different microenvironment (4, 7).”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 2×
“Macrophages are a heterogeneous population of cells derived from monocytes and polarized into two functionally distinct forms, M1 and M2, in response to different microenvironment (4, 7).”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262 · cited 2×
“Although the prognostic significance of TAMs has been studied in several malignant tumors, it remains unclear whether infiltration of TAMs is associated with an improved or worse outcome (9-15, 30).”
BackgroundMacrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074
Cited by
Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages
Barros, M. H. M., Hauck, F., Dreyer, J. H., Kempkes, B., & Niedobitek, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080908 · Cited by 594
Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?
Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., Farronato, G., Bruno, A., & Mortara, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/8917804 · Cited by 508
Peltanova, B., Raudenska, M., & Masarik, M. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0983-5 · Cited by 469
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Larionova, I., Tuguzbaeva, G., Ponomaryova, A., Stakheyeva, M., Cherdyntseva, N., Pavlov, V., Choinzonov, E., & Kzhyshkowska, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566511 · Cited by 392
Rodriguez-Garcia, A., Lynn, R. C., Poussin, M., Eiva, M. A., Shaw, L. C., O’Connor, R. S., Minutolo, N. G., Casado-Medrano, V., Lopez, G., Matsuyama, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20893-2 · Cited by 341
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
Nowak, M., & Klink, M. (2020) · Cells · doi:10.3390/cells9051299 · Cited by 287
Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J. M., Meissner, W., Krause, M., Schwörer, A., Wagner, U., Müller‐Brüsselbach, S., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28335 · Cited by 271
Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases
Skytthe, M. K., Graversen, J. H., & Moestrup, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155497 · Cited by 261
Fu, X.-L., Duan, W., Su, C.-Y., Mao, F.-Y., Lv, Y.-P., Teng, Y.-S., Yu, P.-W., Zhuang, Y., & Zhao, Y.-L. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2052-5 · Cited by 242
Raghavan, S., Mehta, P., Xie, Y., Lei, Y. L., & Mehta, G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0666-1 · Cited by 234
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Chen, L., Shi, Y., Zhu, X., Guo, W., Zhang, M., Che, Y., Tang, L., Yang, X., You, Q., & Liu, Z. (2019) · Oncology Reports · doi:10.3892/or.2019.7206 · Cited by 92
Cornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106742 · Cited by 91
Ciucci, A., Zannoni, G. F., Buttarelli, M., Lisi, L., Travaglia, D., Martinelli, E., Scambia, G., & Gallo, D. (2016) · Oncotarget · doi:10.18632/oncotarget.6943 · Cited by 46
Ciucci, A., Zannoni, G. F., Buttarelli, M., Martinelli, E., Mascilini, F., Petrillo, M., Ferrandina, G., Scambia, G., & Gallo, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10797 · Cited by 27
“com/oncotarget ovarian cancer histological type [18].”
The many microenvironments of ovarian cancer
Micek, H. M., Visetsouk, M. R., Fleszar, A. J., & Kreeger, P. K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_12 · Cited by 14
Metadata
- Authors
- Lan, C., Huang, X., Lin, S., Huang, H., Cai, Q., Wan, T., Lu, J., & Liu, J.
- Venue
- Technology in Cancer Research & Treatment
- Publisher
- SAGE Publications
- Published
- 2013-06
- Volume
- 12
- Issue
- 3
- Pages
- 259-267
- ISSN
- 1533-0338 (ISSN-L)
- 1533-0346
- OpenAlex
- W2170553216
- Cited by
- 227
- References
- 6
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.